The U.S. Food and Drug Administration approved Rybrevant Faspro as a monotherapy on November 5, 2026, according to the FDA prescribing information. Whether an oropharyngeal squamous cell carcinoma is HPV-associated is determined using p16 immunohistochemistry. The cancer is difficult to treat and effective treatment options remain limited, the FDA said, as Reuters reported in ETPharma.
Rybrevant Faspro was previously approved for certain patients with EGFR-mutated non-small cell lung cancer. According to CURE, the new indication is its first approval outside lung cancer. The drug is injected under the skin and targets the proteins EGFR and MET, which can support the growth of cancer cells.

The study behind the approval
The approval is based on the open-label, non-randomized Phase 1b/2 OrigAMI-4 study. Its first cohort examined amivantamab administered subcutaneously every three weeks in participants with non-HPV-associated recurrent or metastatic head and neck squamous cell carcinoma after an anti-PD-(L)1 antibody and platinum-based chemotherapy. The study was published in the Journal of Clinical Oncology. The primary efficacy population comprised 102 patients, according to The ASCO Post. Patients who had previously received anti-EGFR therapy were also excluded. According to the investigators' assessment, the objective response rate was 47 percent. Fifteen percent of participants achieved a complete response, with no remaining signs of cancer. In 56 percent of those who responded, the response lasted at least six months. The overall median duration of response had not yet been reached at the time of reporting. The median follow-up at that point was 11.8 months. Yale oncologist Barbara Burtness, who served as a consultant to Johnson & Johnson, described the observed responses as encouraging for patients in a company press release. According to the manufacturer, all 102 participants experienced adverse events in the study, most commonly rash in 79 percent. This was followed by fatigue in 39 percent and nail problems in 35 percent. Serious adverse reactions were recorded in 39 percent, and adverse events were fatal in 6 percent. According to the manufacturer's own safety analysis, one of the deaths was due to treatment-related pneumonia, while the other five deaths were classified as unrelated to amivantamab.
The benchmark: Nivolumab and the approval history
Before Rybrevant Faspro, nivolumab showed a survival benefit over single-agent therapies in platinum-refractory recurrent head and neck squamous cell carcinoma. The randomized CheckMate-141 study enrolled 361 patients. Median overall survival was 7.5 months with nivolumab, compared with 5.1 months with standard therapy. The response rate was 13.3 percent, compared with 5.8 percent. For single-agent therapies such as paclitaxel or cetuximab after an immune checkpoint inhibitor and chemotherapy, the abstract of the OrigAMI-4 study reports response rates of 21 to 24 percent. A retrospective analysis by Sharma, Gulati and Chopra of 204 oncology approvals shows how often such accelerated approvals in oncology ultimately remain in effect. Of these, 138 had completed their post-approval assessment. Of those, 77.5 percent were converted to regular approvals and 22.5 percent were withdrawn. For solid tumors, the conversion rate was higher, at 82 percent, than for hematological malignancies, at 71 percent.
Accelerated approval: Continued approval may depend on evidence
The approval was based on response rate and duration of response. Its continuation may depend on verification of clinical benefit in a confirmatory study. The randomized Phase 3 OrigAMI-5 study is underway as a confirmatory study. It is testing Rybrevant Faspro together with carboplatin and pembrolizumab as a first treatment in previously untreated recurrent or metastatic head and neck squamous cell carcinoma against a standard therapy of platinum, pembrolizumab and 5-FU. An estimated 600 participants are planned for the study. It started on December 3, 2025, and its primary completion is expected in June 2029. Rybrevant Faspro was reviewed under Project Orbis, in which the FDA collaborated with Brazil's drug regulator ANVISA, Canada's Health Canada, Israel's Ministry of Health and the Health Sciences Agency. According to The ASCO Post, applications to these authorities may still be in the submission or review process.
What could affect the continuation of the approval
Second, according to the analysis by Sharma, Gulati and Chopra, 63 percent of successful conversions of accelerated oncology approvals to regular approvals were based on randomized controlled trials. OrigAMI-5 is designed as a randomized study.
